Result for
Tag: vaccine
June 15, 2021
Allergic Symptoms after mRNA COVID-19 Vaccination and Risk of Incomplete Vaccination
Self-reported allergic symptoms following the first dose of a COVID-19 mRNA vaccine was associated with a 5-fold increase in odds of not completing the second dose after adjusting for demographics, vaccine manufacturer, wave of vaccine eligibility, and other confounders in a prospective cohort of healthcare employees in Boston. Among 61,057 employees who received a first…
June 11, 2021
Does Reactogenicity after a Second Injection of the BNT162b2 Vaccine Predict Spike IgG Antibody Levels in Healthy Japanese Subjects
[Pre-print, not peer-reviewed] A small study of Japanese healthcare workers (N=67) found that reactogenicity to a second dose of the Pfizer-BioNTech vaccine was not a predictor of subsequent IgG antibody levels. The study controlled for age, sex, and IgG levels after the first dose of vaccine. The prevalence of local and systemic reactogenicity was 2.5-times…
June 10, 2021
Highly-Specific Memory B Cells Generation after the 2nd Dose of BNT162b2 Vaccine Compensate for the Decline of Serum Antibodies and Absence of Mucosal IgA
[Pre-print, not peer-reviewed] The Pfizer-BioNTech vaccine only elicited a short-lived mucosal IgA antibody response in a study of 108 vaccinated healthcare workers (HCWs) in Italy without prior infection, with none of the vaccinated HCWs tested for mucosal IgA having a detectable response 2-3 weeks after the second dose. By contrast, the vaccine elicited robust memory…
Neutralizing Antibodies Elicited by the Ad26.COV2.S COVID-19 Vaccine Show Reduced Activity against 501Y.V2 (B.1.351) despite Protection against Severe Disease by This Variant
[Pre-print, not peer-reviewed] Anti-SARS-CoV-2 antibody binding responses among individuals 29 days after vaccination with the single-dose Johnson & Johnson-Janssen vaccine (n=88) were reduced by 1.8-fold against the B.1.351 (Beta) variant compared to the wild-type D614G strain. By contrast, 82% in a subset of 27 individuals showed no neutralizing activity against B.1.351 (Beta) at Day 29…
Immunogenicity of Ad26.COV2.S Vaccine against SARS-CoV-2 Variants in Humans
Median anti-SARS-CoV-2 neutralizing antibody titers of sera from individuals vaccinated with the Johnson & Johnson-Janssen vaccine in the phase 1/2 trials (n=20) were 5- and 3-fold lower against the B.1.351 (Beta) and P.1 (Gamma) variants, respectively, compared with the wild-type strain on day 71 following vaccination. Binding antibody titers were impaired but to a lesser…
June 9, 2021
Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February-March 2021
A SARS-CoV-2 outbreak in a long-term care facility in Germany resulted in a milder disease course, considerably shorter viral RNA shedding (7.5 vs 31 days), and lower peak viral load in vaccinated residents with breakthrough infection compared to unvaccinated residents. The outbreak involved a sequence-confirmed B.1.1.7 (Alpha) variant and resulted in 16 breakthrough infections in…
June 8, 2021
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
The risk of any SARS-CoV-2 infection was reduced by 51% between 13 to 24 days after the first dose of the Pfizer-BioNTech vaccine when compared to a period of 1 to 12 days after vaccination, according to a comparative effectiveness study in Israel (n=503,875). The weighted daily incidence of SARS-CoV-2 infection decreased from 43.4 infections…
June 7, 2021
Neutralising Antibody Activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 Vaccination
A study of the effectiveness of neutralizing antibody titers (NAbTs) against the B.1.617.2 SARS-CoV-2 variant, first identified in India and now widely circulating in the UK, found that two doses of the Pfizer-BioNTech vaccine elicited anti-wild-type spike antibodies in all participants, while NAbTs were reduced 5.8-fold against B.1.617.2 relative to wild-type, a significantly greater reduction…
Adverse Outcomes Associated with SARS-CoV-2 Variant B.1.351 Infection in Vaccinated Residents of a Long Term Care Home, Ontario, Canada
Over a period of 3 weeks, an outbreak at a long-term care facility in Ontario, Canada likely originating from an unvaccinated staff member infected with the B.1.351 variant sickened 4 staff members (2 fully vaccinated, 1 single dose, one unvaccinated) and 9 fully vaccinated residents. Two unvaccinated staff members had infections due to other variants…
Effectiveness of MRNA COVID-19 Vaccines among Employees in an American Healthcare System
[Pre-print, not peer-reviewed] A study of SARS-CoV-2 infections among employees of the Cleveland Clinic Health System found that after adjusting for the slope of the epidemic curve, age, and job type, vaccination was associated with a significantly reduced risk of infection (HR = 0.03), corresponding to a vaccine effectiveness of 97.1%. Vaccine effectiveness was 89.2%…
Next page